410 related articles for article (PubMed ID: 31753002)
21. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
22. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
Jia H; Wang Z; Wang Y; Liu Y; Dai H; Tong C; Guo Y; Guo B; Ti D; Han X; Yang Q; Wu Z; Han W
J Hematol Oncol; 2019 Jun; 12(1):57. PubMed ID: 31182121
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
25. [Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B].
Chung SM; Sohn JH; Kim TY; Yoo KD; Ahn YW; Bae JH; Jeon YC; Choi JH
Korean J Gastroenterol; 2010 Apr; 55(4):266-9. PubMed ID: 20389182
[TBL] [Abstract][Full Text] [Related]
26. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
27. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel JY; Patel S; Muffly L; Hossain NM; Oak J; Baird JH; Frank MJ; Shiraz P; Sahaf B; Craig J; Iglesias M; Younes S; Natkunam Y; Ozawa MG; Yang E; Tamaresis J; Chinnasamy H; Ehlinger Z; Reynolds W; Lynn R; Rotiroti MC; Gkitsas N; Arai S; Johnston L; Lowsky R; Majzner RG; Meyer E; Negrin RS; Rezvani AR; Sidana S; Shizuru J; Weng WK; Mullins C; Jacob A; Kirsch I; Bazzano M; Zhou J; Mackay S; Bornheimer SJ; Schultz L; Ramakrishna S; Davis KL; Kong KA; Shah NN; Qin H; Fry T; Feldman S; Mackall CL; Miklos DB
Nat Med; 2021 Aug; 27(8):1419-1431. PubMed ID: 34312556
[TBL] [Abstract][Full Text] [Related]
28. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
Yang C; Xie M; Zhang K; Liu H; Liang A; Young KH; Qian W
Leukemia; 2020 Nov; 34(11):3055-3059. PubMed ID: 32533094
[No Abstract] [Full Text] [Related]
29. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
30. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract][Full Text] [Related]
31. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
32. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
33. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
[TBL] [Abstract][Full Text] [Related]
34. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
Sanchez MJ; Buti M; Homs M; Palacios A; Rodriguez-Frias F; Esteban R
J Hepatol; 2009 Dec; 51(6):1091-6. PubMed ID: 19836097
[TBL] [Abstract][Full Text] [Related]
35. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
37. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
38. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
[TBL] [Abstract][Full Text] [Related]
39. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
40. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
